Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Aptorum

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Aptorum Group Announces Significant Progress of SACT-1

Contact the Supplier

Lead Product(s): SACT-1

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

Subject to completion of current validation studies, Aptorum Group plans to leverage the 505(b)(2) pathway and submit an IND submission with the FDA for SACT-1 in H2 2020.